China's Luye Pharma has claimed its first FDA approval, getting a green light for Rykindo, an injectable formulation of the antipsychotic risperidone given every two weeks.
Encouraged by new data, Newron Pharmaceuticals has said it will start a registration study of would-be blockbuster evenamide in treatment-resistant schizophrenia (TRS) later this year.
Sosei Heptares has taken another of its partnered G protein-coupled receptor (GPCR) programmes into mid-stage clinical trials, earning a $30 million milestone payment from Neurocrine Biosci
